Proteasome inhibitor-induced model of Parkinson's disease

被引:64
作者
McNaught, Kevin St. P. [1 ]
Olanow, C. Warren [1 ]
机构
[1] Mt Sinai Sch Med, Dept Neurol, Annenberg 14-73,1 Gustave L Levy Pl, New York, NY 10029 USA
关键词
D O I
10.1002/ana.20936
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We recently reported that systemic administration of a proteasome inhibitor induced a progressive levodopa-responsive, bradykinetic syndrome in rats with imaging, pathological, and biochemical features that strikingly resemble what is found in PD. This model has the potential to be a useful tool for studying the mechanism of cell death in Parkinson's disease and for testing putative neuroprotective agents. Since publication of these findings, several laboratories have sought to reproduce the model; some have been successful in replicating our findings, but others have not. The reason for this variability is not known, but resolution is critically important given the potential utility of this model. We have begun to examine various factors that alone or in combination might explain these differences, and we present in this article preliminary results from these studies.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 24 条
[1]   The proteasomal inhibition model of Parkinson's disease: "Boon or bust"? [J].
Beal, Flint ;
Lang, Anthony .
ANNALS OF NEUROLOGY, 2006, 60 (02) :158-161
[2]   Proteasome inhibition and Parkinson's disease modeling [J].
Bove, Jordi ;
Zhou, Chun ;
Jackson-Lewis, Vernice ;
Taylor, Julie ;
Chu, Yaping ;
Rideout, Hardy J. ;
Wu, Du-Chu ;
Kordower, Jeffrey H. ;
Petrucelli, Leonard ;
Przedborski, Serge .
ANNALS OF NEUROLOGY, 2006, 60 (02) :260-264
[3]   Participation of the 26S proteasome in the regulation of progesterone receptor concentrations in the rat brain [J].
Camacho-Arroyo, I ;
Villamar-Cruz, O ;
González-Arenas, A ;
Guerra-Araiza, C .
NEUROENDOCRINOLOGY, 2002, 76 (05) :267-271
[4]  
Fornai F, 2003, J NEUROSCI, V23, P8955
[5]   Pathogenetic mechanisms of parkin in Parkinson's disease [J].
Hattori, N ;
Mizuno, Y .
LANCET, 2004, 364 (9435) :722-724
[6]   Proteasome inhibitors: from research tools to drug candidates [J].
Kisselev, AF ;
Goldberg, AL .
CHEMISTRY & BIOLOGY, 2001, 8 (08) :739-758
[7]   Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys [J].
Kordower, Jeffrey H. ;
Kanaan, Nicholas M. ;
Chu, Yaping ;
Babu, Rangasamy Suresh ;
Stansell, James, III ;
Terpstra, Brian T. ;
Sortwell, Caryl E. ;
Steece-Collier, Kathy ;
Collier, Timothy J. .
ANNALS OF NEUROLOGY, 2006, 60 (02) :264-268
[8]   Lack of nigrostriatal pathology in a rat model of proteasome inhibition [J].
Manning-Bog, Amy B. ;
Reaney, Stephen H. ;
Chou, Vivian P. ;
Johnston, Louisa C. ;
McCormack, Alison L. ;
Johnston, Jennifer ;
Langston, J. William ;
Di Monte, Donato A. .
ANNALS OF NEUROLOGY, 2006, 60 (02) :256-260
[9]   Proteasome inhibition causes nigral degeneration with inclusion bodies in rats [J].
McNaught, KS ;
Björklund, LM ;
Belizaire, R ;
Isacson, O ;
Jenner, P ;
Olanow, CW .
NEUROREPORT, 2002, 13 (11) :1437-1441
[10]   Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures [J].
McNaught, KS ;
Mytilineou, C ;
JnoBaptiste, R ;
Yabut, J ;
Shashidharan, P ;
Jenner, P ;
Olanow, CW .
JOURNAL OF NEUROCHEMISTRY, 2002, 81 (02) :301-306